» Articles » PMID: 218499

Extreme Sensitivity of Enveloped Viruses, Including Herpes Simplex, to Long-chain Unsaturated Monoglycerides and Alcohols

Overview
Specialty Pharmacology
Date 1979 Jan 1
PMID 218499
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Unsaturated monoglycerides and alcohols of chain lengths of 16 or 18 carbons were found to be extremely potent inactivators of two enveloped viruses, herpes simplex virus type 2 and bacteriophage phi6. The lipid-containing bacteriophage PM2 was also inactivated by some of these amphiphilic molecules. Treatment of herpes simplex virus type 2 with these compounds at concentrations as low as 0.2 muM reduced virus survival to 50% in 30 min, making these agents the most potent inactivators of herpes simplex viruses discovered that are not cytotoxic to mammalian cells. Detailed characterizations of the effects of unsaturated monoglycerides and alcohols on bacteriophages phi6 and PM2 showed that the inactivated phi6 virion remained nearly intact but that PM2 was almost completely disrupted by the inactivating treatment. Some of the compounds inactivate the viruses even at low temperature (0 degrees C). Excess amounts of diglycerides and phospholipids interfere with the inactivating abilities of some of the unsaturated monoglycerides and alcohols against phi6 and PM2. Our findings suggest that the unsaturated monoglycerides and some of the unsaturated alcohols should be further studied as potential antiviral agents, particularly for application to herpesvirus-infected areas of the skin and accessible epithelium.

Citing Articles

Bioactive lipid-based therapeutic approach to COVID-19 and other similar infections.

Das U Arch Med Sci. 2023; 19(5):1327-1359.

PMID: 37732033 PMC: 10507771. DOI: 10.5114/aoms/135703.


Essential Fatty Acids and Their Metabolites in the Pathobiology of Inflammation and Its Resolution.

Das U Biomolecules. 2021; 11(12).

PMID: 34944517 PMC: 8699107. DOI: 10.3390/biom11121873.


Activating endogenous resolution pathways by soluble epoxide hydrolase inhibitors for the management of COVID-19.

Manickam M, Meenakshisundaram S, Pillaiyar T Arch Pharm (Weinheim). 2021; 355(3):e2100367.

PMID: 34802171 PMC: 9011438. DOI: 10.1002/ardp.202100367.


The Infectious Bronchitis Coronavirus Pneumonia Model Presenting a Novel Insight for the SARS-CoV-2 Dissemination Route.

Nefedova E, Koptev V, Bobikova A, Cherepushkina V, Mironova T, Afonyushkin V Vet Sci. 2021; 8(10).

PMID: 34679068 PMC: 8540477. DOI: 10.3390/vetsci8100239.


Tear Lipocalin and Lipocalin-Interacting Membrane Receptor.

Glasgow B Front Physiol. 2021; 12:684211.

PMID: 34489718 PMC: 8417070. DOI: 10.3389/fphys.2021.684211.


References
1.
SNIPES W, Person S, Keith A, Cupp J . Butylated hydroxytoluene inactivated lipid-containing viruses. Science. 1975; 188(4183):64-6. DOI: 10.1126/science.163494. View

2.
SNIPES W, Person S, Keller G, Taylor W, Keith A . Inactivation of lipid-containing viruses by long-chain alcohols. Antimicrob Agents Chemother. 1977; 11(1):98-104. PMC: 351925. DOI: 10.1128/AAC.11.1.98. View

3.
Jordan G, Seet E . Antiviral effects of amphotericin B methyl ester. Antimicrob Agents Chemother. 1978; 13(2):199-204. PMC: 352214. DOI: 10.1128/AAC.13.2.199. View

4.
Reinhardt A, Cadden S, Sands J . Inhibitory effect of fatty acids on the entry of the lipid-containing bacteriophage PR4 into Escherichia coli. J Virol. 1978; 25(2):479-85. PMC: 353959. DOI: 10.1128/JVI.25.2.479-485.1978. View

5.
Bamford D, Palva E, Lounatmaa K . Ultrastructure and life cycle of the lipid-containing bacteriophage phi 6. J Gen Virol. 1976; 32(2):249-59. DOI: 10.1099/0022-1317-32-2-249. View